Related Experiment Videos
Calcium channel blockers
1Boston University School of Medicine, Massachusetts.
The Medical Clinics of North America
|January 1, 1988
Insights
Calcium channel blockers, initially for angina, show broad utility. These drugs effectively treat diverse conditions including hypertension, cardiomyopathy, and neurological disorders like migraine.
Area of Science:
- Pharmacology
- Cardiology
- Neurology
Background:
- Calcium channel blockers (CCBs) were first developed for angina treatment.
- Their vasodilatory and electrophysiological effects suggest wider therapeutic potential.
Purpose of the Study:
- To review the expanded therapeutic applications of calcium channel blockers beyond their initial indications.
- To highlight the diverse conditions where CCBs have demonstrated efficacy.
Main Methods:
- Literature review of clinical studies and pharmacological data.
- Analysis of evidence supporting CCB use in various cardiovascular, respiratory, and neurological conditions.
Main Results:
- CCBs are effective in managing pulmonary and systemic hypertension.
- Evidence supports their use in hypertrophic cardiomyopathy, arrhythmias, and Raynaud's syndrome.
- Emerging data indicate utility in asthma, esophageal spasm, cerebral arterial spasm, and migraine.
Conclusions:
- Calcium channel blockers possess a broader therapeutic spectrum than initially recognized.
- Their versatile mechanisms of action make them valuable in treating a wide array of medical conditions.
- Further research may uncover additional applications for these essential medications.
Abstract:
The calcium channel blockers initially were approved for the treatment of classical and variant angina pectoris. Recent studies indicate that these agents also are useful in such diverse conditions as pulmonary and systemic hypertension, hypertrophic cardiomyopathy, arrhythmias, asthma, Raynaud's syndrome, esophageal spasm, myometrial hyperactivity, cerebral arterial spasm, and migraine.